Bruce Greenberg
Interim Chief Financial Officer
Replay available
Aldeyra Therapeutics, Inc. (ALDX) Q4 2022 Earnings Call
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Q4 2022 earnings conference call, held 2023-03-09. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Todd Brady
President and Chief Executive Officer
Mark Goodman
SVB Securities
Yigal Notremovic
Citigroup
Justin Kim
Oppenheimer & Co.
Kelly Shee
Jefferies
Tom Schrader
BTIG (question asked via Sungwon)
Yeo Jen
Laid Law Company
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Aldeyra Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.109 -- 00:00:05.171 Ladies and gentlemen, thank you for standing by and welcome to the Algea therapeutic 00:00:05.171 -- 00:00:09.452 full year 2022 financial results conference call. 00:00:09.452 -- 00:00:13.094 At this time, all participants are in a listen only mode. 00:00:13.094 -- 00:00:16.815 After the speaker's presentations, there will be a question and answer session. 00:00:16.815 -- 00:00:21.757 I would now like to hand the conference call over to Mr. 00:00:21.757 -- 00:00:25.938 Bruce Greenberg, the company's interim chief financial officer. 00:00:25.938 -- 00:00:29.019 Please go ahead, Bruce Greenberg. 00:00:29.656 -- 00:00:33.498 Thank you, and good morning, everyone. With me today is Dr. 00:00:33.498 -- 00:00:37.439 Todd Brady, our President and Chief Executive Officer. 00:00:37.439 -- 00:00:42.001 This morning, we issued a press release reporting recent corporate highlights and our 00:00:42.001 -- 00:00:46.553 financial results for the year ended December 31st, 2022. 00:00:46.663 -- 00:00:51.406 A copy of the press release is available on the Investors in Media section of our website 00:00:51.406 -- 00:00:53.826 at www.aldera.com. 00:00:56.479 -- 00:01:00.461 Please note that this morning's conference call contains forward-looking statements regarding 00:01:00.461 -- 00:01:04.543 future events and the future performance of LDR. 00:01:04.543 -- 00:01:09.305 Forward-looking statements include, but are not limited to, statements regarding FDA 00:01:09.305 -- 00:01:11.165 review of 00:01:11.165 -- 00:01:15.747 our new drug applications, potential commercialization, 00:01:15.747 -- 00:01:20.570 the anticipated timing of initiation of results from our clinical trials, a projected 00:01:20.570 -- 00:01:25.885 cash runway, are possible or assum...